| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IkBKb |
| Uniprot No | O14920 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-756aa |
| 氨基酸序列 | MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCTSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS |
| 预测分子量 | 92.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IKKβ(IkB kinase β)重组蛋白的3条参考文献示例，涵盖结构、功能及应用研究：
1. **"Expression and crystal structure determination of recombinant IKKβ kinase domain"**
*作者：Yamauchi et al.*
**摘要**：通过大肠杆菌重组表达IKKβ激酶结构域，解析其晶体结构，揭示ATP结合口袋的构象特征，为靶向药物设计提供结构基础。
2. **"Functional characterization of recombinant IKKβ in NF-κB signaling"**
*作者：DiDonato et al.*
**摘要**：利用重组IKKβ蛋白进行体外激酶实验，证实其对IκBα的高效磷酸化能力，阐明其在NF-κB信号通路激活中的核心作用及调控机制。
3. **"High-throughput screening of IKKβ inhibitors using recombinant protein"**
*作者：Karin et al.*
**摘要**：基于重组IKKβ蛋白建立高通量筛选平台，鉴定出多个特异性小分子抑制剂，为炎症性疾病和癌症治疗提供潜在药物先导化合物。
4. **"Site-directed mutagenesis of recombinant IKKβ reveals critical phosphorylation sites"**
*作者：Chen et al.*
**摘要**：通过重组IKKβ蛋白的定点突变分析，发现Ser177/Ser181位点的磷酸化对其激酶活性至关重要，为研究IKKβ功能调控提供分子依据。
(注：上述作者与文献为示例性内容，实际引用时需核实具体文献信息。)
**Background of IκB Kinase Beta (IKKβ) Recombinant Protein**
IκB kinase beta (IKKβ), also known as IKK2. is a critical serine/threonine kinase within the IKK complex, which regulates the NF-κB signaling pathway—a central mediator of immune, inflammatory, and stress responses. The IKK complex, composed of IKKα, IKKβ, and the regulatory subunit NEMO/IKKγ, phosphorylates the inhibitor of kappa B (IκB) proteins, leading to their proteasomal degradation. This releases NF-κB transcription factors, enabling their nuclear translocation and activation of target genes involved in cell survival, proliferation, and cytokine production.
IKKβ is the primary kinase responsible for canonical NF-κB activation in response to pro-inflammatory stimuli (e.g., TNF-α, IL-1β, or pathogen-associated molecular patterns). Dysregulation of IKKβ is linked to chronic inflammation, autoimmune diseases, and cancer, making it a therapeutic target. Recombinant IKKβ proteins are engineered using expression systems (e.g., *E. coli* or mammalian cells) to retain enzymatic activity and structural integrity. These proteins are purified via affinity tags (e.g., His-tag) and validated through kinase assays and Western blotting.
Structurally, recombinant IKKβ includes key domains like the kinase domain, leucine zipper, and helix-loop-helix motifs, essential for its function and interaction with other complex components. Researchers utilize recombinant IKKβ to study NF-κB signaling mechanisms, screen inhibitors, or model diseases in vitro. Its application extends to drug discovery, particularly in developing anti-inflammatory and anti-cancer agents. By enabling precise biochemical and structural studies, recombinant IKKβ has become indispensable for dissecting NF-κB-related pathologies and advancing targeted therapies.
×
